Dexrazoxane improves cardiac autonomic function in epirubicin-treated breast cancer patients with type 2 diabetes

Medicine (United States)

Volumn 95, Issue 44, 2016, Pages

  Sun, Fangyi ^a   Shi, Jing ^b   Geng, Cuizhi ^c  

^a Department of Cardiology ^*  (China)

^b Office of Scientific Research   (China)

^c HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

Breast cancer; Dexrazoxane; Diabetes; Epirubicin; Heart rate variability; Resting heart rate

Indexed keywords

ANTINEOPLASTIC AGENT; EPIRUBICIN; RAZOXANE;

AUTONOMIC NERVOUS SYSTEM; BREAST NEOPLASMS; COMPLICATION; CONTROLLED STUDY; DRUG EFFECTS; FEMALE; HEART; HUMAN; INNERVATION; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

ANTINEOPLASTIC AGENTS; AUTONOMIC NERVOUS SYSTEM; BREAST NEOPLASMS; DEXRAZOXANE; DIABETES MELLITUS, TYPE 2; EPIRUBICIN; FEMALE; HEART; HUMANS; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 84995970255     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000005228     Document Type: Article

References (31)

1. Hayek ER, Speakman E, Rehmus E. Acute doxorubicin cardiotoxicity.N Engl J Med 2005;352:2456-7.
2. Kaklamani VG, Gradishar WJ. Epirubicin versus doxorubicin: which is the anthracycline of choice for the treatment of breast cancer? Clin Breast Cancer 2003;4(suppl 1):S26-33.
3. Postma A, Elzenga NJ, Haaksma J, et al. Cardiac status in bone tumor survivors up to nearly 19 years after treatment with doxorubicin: a longitudinal study. Med Pediatr Oncol 2002;39:86-92.
4. Brouwer CA, Gietema JA, van den Berg MP, et al. Long-term cardiac follow-up in survivors of a malignant bone tumour. Ann Oncol 2006; 17:1586-91.
5. Syvanen K, Ekholm E, Anttila K, et al. Immediate effects of docetaxel alone or in combination with epirubicin on cardiac function in advanced breast cancer. Anticancer Res 2003;23:1869-73.
6. Viniegra M, Marchetti M, Losso M, et al. Cardiovascular autonomic function in anthracycline-treated breast cancer patients. Cancer Chemother Pharmacol 1990;26:227-31.
7. Khouri MG, Douglas PS, Mackey JR, et al. Cancer therapy-induced cardiac toxicity in early breast cancer: addressing the unresolved issues. Circulation 2012;126:2749-63.
8. Kremer LC, van Dalen EC. Dexrazoxane in children with cancer: from evidence to practice. J Clin Oncol 2015;33:2594-6.
9. Conway A, McCarthy AL, Lawrence P, et al. The prevention, detection and management of cancer treatment-induced cardiotoxicity: a metareview. BMC Cancer 2015;15:366.
10. Marty M, Espie M, Llombart A, et al. Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane®) in advanced/metastatic breast cancer patients treated with anthracyclinebased chemotherapy. Ann Oncol 2006;17:614-22.
11. Choi HS, Park ES, Kang HJ, et al. Dexrazoxane for preventing anthracycline cardiotoxicity in children with solid tumors. J Korean Med Sci 2010;25:1336-42.
12. Testore F, Milanese S, Ceste M, et al. Cardioprotective effect of dexrazoxane in patients with breast cancer treated with anthracyclines in adjuvant setting: a 10-year single institution experience. AmJ Cardiovasc Drugs 2008;8:257-63.
13. Yeh ET, Tong AT, Lenihan DJ, et al. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation 2004;109:3122-31.
14. American Diabetes AssociationStandards of medical care in diabetes-2014. Diabetes Care 2014;37(suppl 1):S14-80.
15. Michels KB, Solomon CG, Hu FB, et al. Type 2 diabetes and subsequent incidence of breast cancer in the Nurses' Health Study. Diabetes Care 2003;26:1752-8.
16. Lipscombe LL, Fischer HD, Austin PC, et al. The association between diabetes and breast cancer stage at diagnosis: a population-based study. Breast Cancer Res Treat 2015;150:613-20.
17. Boyle P, Boniol M, Koechlin A, et al. Diabetes and breast cancer risk: a meta-analysis. Br J Cancer 2012;107:1608-17.
18. Zambetti M, Moliterni A, Materazzo C, et al. Long-term cardiac sequelae in operable breast cancer patients given adjuvant chemotherapy with or without doxorubicin and breast irradiation. J Clin Oncol 2001;19:37-43.
19. Armstrong GT, Oeffinger KC, Chen Y, et al. Modifiable risk factors and major cardiac events among adult survivors of childhood cancer. J Clin Oncol 2013;31:3673-80.
20. Vinik AI, Maser RE, Mitchell BD, et al. Diabetic autonomic neuropathy. Diabetes Care 2003;26:1553-79.
21. Sun F, Qi X, Geng C, et al. Dexrazoxane protects breast cancer patients with diabetes from chemotherapy-induced cardiotoxicity. Am J Med Sci 2015;349:406-12.
22. Goldenberg R, Punthakee Z. Canadian Diabetes Association Clinical Practice Guidelines Expert CommitteeDefinition, classification and diagnosis of diabetes, prediabetes and metabolic syndrome. Can J Diabetes 2013;37(suppl 1):S8-11.
23. Nauman J, Janszky I, Vatten LJ, et al. Temporal changes in resting heart rate and deaths from ischemic heart disease. JAMA 2011;306:2579-87.
24. Appel ML, Berger RD, Saul JP, et al. Beat to beat variability in cardiovascular variables: noise or music? J Am Coll Cardiol 1989;14: 1139-48.
25. Schuster AK, Fischer JE, Thayer JF, et al. Decreased heart rate variability correlates to increased cardiovascular risk. Int J Cardiol 2016;203: 728-30.
26. Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Circulation 1996;93:1043-65.
27. Nousiainen T, Vanninen E, Jantunen E, et al. Neuroendocrine changes during the evolution of doxorubicin-induced left ventricular dysfunction in adult lymphoma patients. Clin Sci (Lond) 2001;101:601-7.
28. Pfister R, Michels G, Sharp SJ, et al. Resting heart rate and incident heart failure in apparently healthy men and women in the EPIC-Norfolk study. Eur J Heart Fail 2012;14:1163-70.
29. Senkus E, Jassem J. Cardiovascular effects of systemic cancer treatment. Cancer Treat Rev 2011;37:300-11.
30. Khoharo HK, Halepoto AW. QTc-interval, heart rate variability and postural hypotension as an indicator of cardiac autonomic neuropathy in type 2 diabetic patients. J Pak Med Assoc 2012;62:328-31.
31. Li X, Jiang YH, Jiang P, et al. Analysis of heart rate variability and cardiac autonomic nerve remodeling in streptozotocin-induced diabetic rats. Exp Clin Endocrinol Diabetes 2015;123:272-81.